Entecavir is a deoxyguanosine nucleoside analogue with antiviral activity against the hepatitis B virus (HBV). The compound has a mechanism of action by inhibiting priming and chain extension through inhibition of HBV DNA polymerase. Entecavir is also documented as the most potent HBV DNA polymerase inhibitor and superior to Lamivudine (sc-221830) due to its effectiveness against Lamivudine resistant HBV strains and being 30 fold more active.
1. Thomas, H., et al. 2003. J. Hepatol. 39: S93-S98. PMID: 14708685
2. Rivkin, A. 2007. Drugs Today. 43: 201-220. PMID: 17460784
See how others have used Entecavir. Click on the entry to view the PubMed entry .
PMID: # 26779022 Mandíková, J. et al. 2015. Frontiers in pharmacology. 6: 304.
PMID: # 25550158 Tsukuda, S. et al. 2015. J. Biol. Chem. 290: 5673-84.
PMID: # 24126184 Vlčková, H. et al. 2014. J Pharm Biomed Anal. 88: 337-44.
PMID: # 24025329 Watashi, K. et al. 2013. J. Biol. Chem. 288: 31715-27.
PMID: # 22520634 Nováková, L. et al. 2012. J Chromatogr A. 1259: 237-43.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.